NF2 loss was shown to sensitize to both PI3K and mTOR inhibitors.6, 11 Only four MPM lines expressed NF2 protein (NCI-H2452, ACC-Meso-4, MSTO-211H and Mero-25), consistent with previous studies.6, 24, 25 Of the four lines, three (NCI-H2452, ACC-Meso-4, MSTO-211H) have documented wild-type NF2 according to CCLE database and published data.24, 26 Because only few lines express proven wild-type NF2, it is difficult to draw any conclusion about any correlation between NF2 status and sensitivity and resistance to dual PI3K/mTOR inhibitors in our experimental settings. This evidence concerns the gene NF2 and adrenal cortex carcinoma.